Skip to main content

US ClosedU.S. Closed

Healthcare · Biotechnology

RenovoRx, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing therapies for solid tumor malignancies.

52W Range

99thpctl

Volume

3.15×avg

Market Cap

75.24MUSD

P/E Ratio

-5.3TTM

Div Yield

-ann

Loading chart data...

Current StateState loading

RenovoRx, Inc.

RNXTNASDAQ Capital Market·USD·Closed

RenovoRx, Inc.

RNXTNASDAQ·USD·Closed

$1.67

+12.84%

$1.67

+$0.19 (12.84%)

52W Range

99thpctl

Volume

3.15×avg

Mkt Cap

75.24MUSD

P/E

-5.3TTM

Div Yield

–ann

RNXT: RenovoRx, Inc. Stock Analysis | finqOS